Estrogen controls lipolysis by up-regulating alpha2A-adrenergic receptors directly in human adipose tissue through the estrogen receptor alpha

Author(s): Pedersen SB, Kristensen K, Hermann PA, Katzenellenbogen JA, Richelsen B


Estrogen seems to promote and maintain the typical female type of fat distribution that is characterized by accumulation of adipose tissue, especially in the sc fat depot, with only modest accumulation of adipose tissue intraabdominally. However, it is completely unknown how estrogen controls the fat accumulation. We studied the effects of estradiol in vivo and in vitro on human adipose tissue metabolism and found that estradiol directly increases the number of antilipolytic alpha2A-adrenergic receptors in sc adipocytes. The increased number of alpha2A-adrenergic receptors caused an attenuated lipolytic response of epinephrine in sc adipocytes; in contrast, no effect of estrogen on alpha2A-adrenergic receptor mRNA expression was observed in adipocytes from the intraabdominal fat depot. These findings show that estrogen lowers the lipolytic response in sc fat depot by increasing the number of antilipolytic alpha2A-adrenergic receptors, whereas estrogen seems not to affect lipolysis in adipocytes from the intraabdominal fat depot. Using estrogen receptor subtype-specific ligands, we found that this effect of estrogen was caused through the estrogen receptor subtype alpha. These findings demonstrate that estrogen attenuates the lipolytic response through up-regulation of the number of antilipolytic alpha2A-adrenergic receptors only in sc and not in visceral fat depots. Thus, our findings offer an explanation how estrogen maintains the typical female sc fat distribution because estrogen seems to inhibit lipolysis only in sc depots and thereby shifts the assimilation of fat from intraabdominal depots to sc depots.

Similar Articles

Triglyceride metabolism in pregnancy

Author(s): Ghio A, Bertolotto A, Resi V, Volpe L, Di Cianni G

Energy metabolism during human pregnancy

Author(s): Forsum E, Löf M

Clinical and biochemical features of fatty acid oxidation disorders

Author(s): Rinaldo P, Raymond K, al-Odaib A, Bennett MJ

Plasma carnitine levels of pregnant adolescents in labor

Author(s): Koumantakis E, Sifakis S, Koumantaki Y, Hassan E, Matalliotakis I, et al.

Pregnancy-related changes of carnitine and acylcarnitine concentrations of plasma and erythrocytes

Author(s): Schoderbeck M, Auer B, Legenstein E, Genger H, Sevelda P, et al.

Carnitine status and lactate increase in patients with type I juvenile diabetes

Author(s): Evangeliou A, Gourgiotis D, Karagianni C, Markouri M, Anogianaki N, et al.

The effect of the mode of delivery on the maternal-neonatal carnitine blood levels and antioxidant status

Author(s): Schulpis KH, Papakonstantinou ED, Vlachos GD, Vlachos DG, Antsaklis A, et al.

Current understanding of placental fatty acid transport

Author(s): Gil-Sánchez A, Koletzko B, Larqué E

Maternal lipid metabolism and placental lipid transfer

Author(s): Herrera E, Amusquivar E, López-Soldado I, Ortega H

Blood ketone monitoring: a comparison between gestational diabetes and non-diabetic pregnant women

Author(s): Gin H, Vambergue A, Vasseur C, Rigalleau V, Dufour P, et al.

Determination of free L-carnitine levels in type II diabetic women with and without complications

Author(s): Poorabbas A, Fallah F, Bagdadchi J, Mahdavi R, Aliasgarzadeh A, et al.

Oxidative metabolism in insulin-treated gestational diabetes mellitus

Author(s): Hsu HW, Butte NF, Wong WW, Moon JK, Ellis KJ, et al.

Expression, localization, and function of the carnitine transporter octn2 (slc22a5) in human placenta

Author(s): Grube M, Meyer Zu Schwabedissen H, Draber K, Präger D, Möritz KU, et al.

High activity of fatty acid oxidation enzymes in human placenta: implications for fetal-maternal disease

Author(s): Oey NA, den Boer ME, Ruiter JP, Wanders RJ, Duran M, et al.

Long-chain fatty acid oxidation during early human development

Author(s): Oey NA, den Boer ME, Wijburg FA, Vekemans M, Augé J, et al.